hRad17在浸润性乳腺癌中的表达及临床病理意义  

Expression of hRad17 in breast cancer and its clinical significance

作　　者：田秀春[1,2] 范钦和[1] 顾学文[2] 王翠梅[2] 

机构地区：[1]南京医科大学第一附属医院病理科,江苏南京210029 [2]扬州大学附属苏北人民医院病理科,江苏扬州225001

出　　处：《现代肿瘤医学》2009年第12期2313-2316,共4页Journal of Modern Oncology

摘　　要：目的:探讨hRad17蛋白在乳腺癌中的表达及其意义。方法:采用免疫组化S-P二步法检测90例浸润性乳腺癌、20例良性乳腺组织中hRad17蛋白的表达情况,并分析其临床病理意义。结果:hRad17在浸润性乳腺癌组织及良性乳腺组织中表达分别为62.2%、10%,差异有显著意义(P<0.05)。浸润性乳腺癌组织中hRad17蛋白表达与浸润性乳腺癌的病理分级及淋巴结转移呈正相关(P<0.05),与Ki-67亦呈正相关(P<0.05),与p53、ER、PR及C-erbB-2表达等无相关性。结论:hRad17蛋白表达在乳腺癌的发生、演变过程中起重要作用。并提示浸润性乳腺癌的不良预后,可作为预测乳腺癌预后的参考指标之一。Objective：To study the significance of hRad17 in breast cancer. Methods： S- P immunohistochemical method was used to assess the expression of hRadl7 invasive breast cancer and benign breast tissues. The clinical pathological significance of hRad17 expression was evaluated. Results： The expression of hRad17 in invasive breast cancer and benign breast tissues were 62.2%, 10.0% respectively（ P 〈 0.05 ）. The expression of hRad17 in invasive breast cancer was associated with pathological grade of breast cancer and lymph node metastasis and ki - 67, and not associated with p53, ER, PR and C -erbB- 2. Conclusion： hRad17 may play an important role in the development of breast cancer. The expression of hRad17 is associated with poor prognosis of breast cancer,which could be used to predict the prognosis of breast cancer.

关 键 词：乳腺肿瘤 HRAD17 免疫组织化学 预后 

分 类 号：R737.9[医药卫生—肿瘤]